A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

2023-508279-36-00 Protocol 219728 Human pharmacology (Phase I) - Other Ended

Start 22 May 2024 · End 22 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 219728

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 60
Countries 1
Sites 1

Healthy volunteers

Key facts

Sponsor
Glaxosmithkline Research & Development Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
22 May 2024 → 22 Oct 2024
Decision date (initial)
2024-05-21
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers

VersionLevelCodeTermSystem organ class
20.0 PT 10003553 Asthma 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Glaxosmithkline Research & Development Limited

Sponsor organisation
Glaxosmithkline Research & Development Limited
Address
G S K House, 980 Great West Road 980 Great West Road
City
Brentford
Postcode
TW8 9GS
Country
United Kingdom

Scientific contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 60 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-05-22 2024-10-22 2024-06-04 2024-09-25

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-28 Netherlands Acceptable
2024-05-21
2024-05-21